Data from the LOXO-TRK-14001, SCOUT, and NAVIGATE trials support the full approval of larotrectinib in NTRK gene fusion-positive tumors.
Approval Alert | Larotrectinib in Adult and Pediatric NTRK+ Solid Tumors
Advertisement
Advertisement
Trending on CancerNetwork
1
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
2
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
3
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
4
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
5
